(Q35103364)

English

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). (English)

1 reference

Europe PubMed Central

6 August 2017

phase II clinical trial

0 references

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

adenoid cystic carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Barbara Burtness

3

object named as

Barbara Burtness

1 reference

Europe PubMed Central

6 August 2017

author name string

Athanassios Argiris

1

1 reference

Europe PubMed Central

6 August 2017

Musie Ghebremichael

2

1 reference

Europe PubMed Central

6 August 2017

Rita S Axelrod

4

1 reference

Europe PubMed Central

6 August 2017

Ronald C Deconti

5

1 reference

Europe PubMed Central

6 August 2017

Arlene A Forastiere

6

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

18 January 2011

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

117

1 reference

Europe PubMed Central

6 August 2017

15

1 reference

Europe PubMed Central

6 August 2017

3374-3382

1 reference

Europe PubMed Central

6 August 2017

NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Systemic therapy in the palliative management of advanced salivary gland cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Distant metastasis in adenoid cystic carcinoma of salivary origin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

9 July 2018

Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

The proteasome inhibitor PS-341 in cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135694

27 September 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25852

21 January 2018

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25852

21 January 2018

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for adenocystic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adenoid cystic carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine treatment of recurrent salivary gland carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

1 reference

https://pubmed.ncbi.nlm.nih.gov/21246525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25852

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35103364&oldid=1976442510"